Domenico Mallardo

3.4k total citations · 1 hit paper
35 papers, 861 citations indexed

About

Domenico Mallardo is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Domenico Mallardo has authored 35 papers receiving a total of 861 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 15 papers in Immunology and 14 papers in Molecular Biology. Recurrent topics in Domenico Mallardo's work include Cancer Immunotherapy and Biomarkers (23 papers), Melanoma and MAPK Pathways (11 papers) and Immunotherapy and Immune Responses (10 papers). Domenico Mallardo is often cited by papers focused on Cancer Immunotherapy and Biomarkers (23 papers), Melanoma and MAPK Pathways (11 papers) and Immunotherapy and Immune Responses (10 papers). Domenico Mallardo collaborates with scholars based in Italy, United States and Malaysia. Domenico Mallardo's co-authors include Paolo A. Ascierto, Gabriele Madonna, Mariaelena Capone, Antonio Maria Grimaldi, Diana Giannarelli, Ester Simeone, Corrado Caracò, Vito Vanella, Lucia Festino and Ernesta Cavalcanti and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and International Journal of Molecular Sciences.

In The Last Decade

Domenico Mallardo

31 papers receiving 851 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

2018 351 citations Mariaelena Capone, Diana Giannarelli et al. Journal for ImmunoTherapy of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Domenico Mallardo Italy	12	554	287	254	166	104	35	861
Eleonora Ghisoni Italy	14	463 0.8×	236 0.8×	265 1.0×	167 1.0×	152 1.5×	35	861
Ehsan Malek United States	15	538 1.0×	245 0.9×	744 2.9×	261 1.6×	95 0.9×	113	1.3k
Claudia Felici Italy	15	357 0.6×	156 0.5×	534 2.1×	419 2.5×	125 1.2×	26	1.0k
Yavar Shiravand Italy	7	493 0.9×	285 1.0×	214 0.8×	66 0.4×	147 1.4×	9	844
Habib Sadeghirad Australia	7	509 0.9×	298 1.0×	238 0.9×	82 0.5×	146 1.4×	14	837
Zhi-Ming Shao China	13	344 0.6×	169 0.6×	376 1.5×	215 1.3×	136 1.3×	29	855
Sofia Genta Canada	12	434 0.8×	170 0.6×	289 1.1×	135 0.8×	139 1.3×	36	742
Keyi Jia China	13	441 0.8×	234 0.8×	276 1.1×	111 0.7×	196 1.9×	27	730
Susanna V. Ulahannan United States	17	524 0.9×	197 0.7×	324 1.3×	168 1.0×	192 1.8×	89	1.1k
Bruno A. Duso Italy	9	422 0.8×	189 0.7×	354 1.4×	255 1.5×	186 1.8×	21	879

Countries citing papers authored by Domenico Mallardo

Since Specialization

Citations

This map shows the geographic impact of Domenico Mallardo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Domenico Mallardo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Domenico Mallardo more than expected).

Fields of papers citing papers by Domenico Mallardo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Domenico Mallardo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Domenico Mallardo. The network helps show where Domenico Mallardo may publish in the future.

Co-authorship network of co-authors of Domenico Mallardo

This figure shows the co-authorship network connecting the top 25 collaborators of Domenico Mallardo. A scholar is included among the top collaborators of Domenico Mallardo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Domenico Mallardo. Domenico Mallardo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Palla, Marco, Corrado Caracò, Anna Maria Anniciello, et al.. (2025). Where Reflectance Confocal Microscopy Provides the Greatest Benefit for Diagnosing Skin Cancers: The Experience of the National Cancer Institute of Naples. Cancers. 17(11). 1745–1745.

Volzone, Francesco, Cristina Becchimanzi, Stefania Crisci, et al.. (2024). Long-term complete remission in a patient with high-risk primary mediastinal B-cell lymphoma and iatrogenic symptomatic bradycardia after only two courses of DA-EPOCH-R followed by chemo-free treatment. Annals of Hematology. 103(11). 4759–4764.

Mallardo, Domenico, Jakob Vowinckel, Michael Bailey, et al.. (2024). A Combined Proteomic and Transcriptomic Signature Is Predictive of Response to Anti-PD-1 Treatment: A Retrospective Study in Metastatic Melanoma Patients. International Journal of Molecular Sciences. 25(17). 9345–9345. 6 indexed citations

Ottaviano, Margaret, Domenico Mallardo, Maria Grazia Vitale, et al.. (2024). Impact of sex on immune-related adverse events in patients with melanoma.. Journal of Clinical Oncology. 42(16_suppl). e21548–e21548.

Ascierto, Paolo A., Pietro Quaglino, Francesco Spagnolo, et al.. (2024). Combination or sequence of vemurafenib, cobimetinib, and atezolizumab in high-risk, resectable melanoma (NEO-TIM): Primary results.. Journal of Clinical Oncology. 42(17_suppl). LBA9513–LBA9513. 2 indexed citations

Mallardo, Domenico, Margaret Ottaviano, Maria Grazia Vitale, et al.. (2024). ICOSLG Is Associated with Anti-PD-1 and Concomitant Antihistamine Treatment Response in Advanced Melanoma. International Journal of Molecular Sciences. 25(22). 12439–12439. 1 indexed citations

Galati, Domenico, Serena Zanotta, Mariaelena Capone, et al.. (2023). Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients. Journal of Translational Medicine. 21(1). 318–318. 8 indexed citations

Mallardo, Domenico, Andrew White, Margaret Ottaviano, et al.. (2023). CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy. Journal of Translational Medicine. 21(1). 610–610. 19 indexed citations

Ascierto, Paolo A., Paolo Bossi, Mario Mandalà, et al.. (2023). NEO-CESQ study: Neoadjuvant plus adjuvant treatment with cemiplimab in surgically resectable, high risk stage III/IV (M0) cutaneous squamous cell carcinoma.. Journal of Clinical Oncology. 41(16_suppl). 9576–9576. 11 indexed citations

10.

Cristiani, Costanza Maria, Mariaelena Capone, Cinzia Garofalo, et al.. (2022). Altered Frequencies and Functions of Innate Lymphoid Cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors. Frontiers in Immunology. 13. 811131–811131. 11 indexed citations

11.

Cristinziano, Leonardo, Luca Modestino, Mariaelena Capone, et al.. (2022). PD-L1+ neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab. Frontiers in Immunology. 13. 962669–962669. 5 indexed citations

12.

Scognamiglio, Giosuè, Mariaelena Capone, Francesco Sabbatino, et al.. (2021). The Ratio of GrzB+ − FoxP3+ over CD3+ T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma. Cancers. 13(10). 2325–2325. 9 indexed citations

13.

Madonna, Gabriele, Giuseppe Masucci, Mariaelena Capone, et al.. (2021). Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy. Cancers. 13(16). 4164–4164. 7 indexed citations

14.

Simeone, Ester, Giosuè Scognamiglio, Mariaelena Capone, et al.. (2021). A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation. Journal of Translational Medicine. 19(1). 17–17. 5 indexed citations

15.

Vowinckel, Jakob, Martin Soste, Domenico Mallardo, et al.. (2020). 229 Discovery of ganglioside GM2 activator as a novel proteomic biomarker associated with response to treatment in first-line melanoma subjects treated with PD-1 immunotherapy. Regular and Young Investigator Award Abstracts. A137.1–A137.

16.

Ruggiero, Ciro Francesco, Debora Malpicci, Luigi Fattore, et al.. (2019). ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin. Cancers. 11(10). 1425–1425. 22 indexed citations

17.

Capone, Mariaelena, Diana Giannarelli, Domenico Mallardo, et al.. (2018). Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. Journal for ImmunoTherapy of Cancer. 6(1). 74–74. 351 indexed citations breakdown →

18.

Fattore, Luigi, Ciro Francesco Ruggiero, Maria Elena Pisanu, et al.. (2018). Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma. Cell Death and Differentiation. 26(7). 1267–1282. 53 indexed citations

19.

Madonna, Gabriele, Carmen Ballesteros‐Merino, Zipei Feng, et al.. (2017). PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. OncoImmunology. 7(12). e1405206–e1405206. 46 indexed citations

20.

Morello, Silvana, Mariaelena Capone, Claudia Sorrentino, et al.. (2017). Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab. Journal of Translational Medicine. 15(1). 244–244. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact